NASDAQ · Biotechnology

Foghorn Therapeutics Inc. (FHTX) Stock

$5.20 +7.22% NASDAQ: FHTX Healthcare

Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines.

Valuation

MetricValue
Price$5.20
Market Cap$305.31M
P/E Ratio-4.15
P/B Ratio-4.41
P/S Ratio10.09
EPS (TTM)$-1.18
52-Week High$6.95
52-Week Low$3.27
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE85.78%
ROA-33.90%
ROCE-51.20%
Gross Margin-264.52%
Operating Margin-264.52%
Net Margin-266.88%
Debt/Equity-0.55
Current Ratio2.72

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$19.0M$34.0M$23.0M$31.0M
Operating Profit$-101.0M$-117.0M$-108.0M$-103.0M$-82.0M
Net Profit$-101.0M$-109.0M$-98.0M$-87.0M$-74.0M
EPS$-2.78$-2.62$-2.34$-1.58$-1.18
Op Margin-7637.1%-609.2%-315.9%-454.3%-265.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$520.0M$405.0M$286.0M$284.0M$198.0M
Total Liabilities$423.0M$405.0M$363.0M$330.0M$307.0M
Cash$101.0M$52.0M$80.0M$55.0M$81.0M
Borrowings$58.0M$52.0M$45.0M$37.0M$41.0M

Latest News

Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains? Zacks · Jul 3, 2026 Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 GlobeNewswire · Jun 5, 2026 Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May GlobeNewswire · May 12, 2026 The Foghorn Therapeutics Inc. (NASDAQ:FHTX) First-Quarter Results Are Out And Analysts Have Published New Forecasts Simply Wall St. · May 11, 2026 CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks · May 7, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-50.0M$194.0M$-118.0M$-100.0M$-86.0M
Investing Cash Flow$33.0M$-246.0M$143.0M$-31.0M$112.0M
Financing Cash Flow$1.0M$0$2.0M$2.0M$0
Net Cash Flow$8.0M$-49.0M$28.0M$-25.0M$27.0M
Free Cash Flow$-54.0M$192.0M$-119.0M$-101.0M$-86.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.28
EV / EBITDA-3.56
FCF Yield-28.17%
Quick Ratio2.72
Interest Coverage0.00
Return 1Y-21.64%
Return 3Y-38.55%
Return 5Y-43.01%

Ownership

Insiders Held14.30%
Institutions Held76.58%
Institutions Float Held89.35%
Institutional HolderSharesReport Date
Flagship Pioneering LLC12,674,1202026-03-31
FMR, LLC6,047,1982026-03-31
BVF Inc.5,842,0002026-03-31
Deerfield Management Company, L.P4,394,3672026-03-31
Raymond James Financial, Inc.2,602,3822026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARCT $6.26 +0.64% -2.93 $177.93M 0.00%
ASMB $26.68 +0.87% -51.53 $424.02M 0.00%
ENTA $12.61 -0.94% -6.04 $366.68M 0.00%
HUMA $0.66 -1.79% -4.19 $110.81M 0.00%
IMRX $4.24 -2.75% -3.94 $153.92M 0.00%

About Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.

Foghorn Therapeutics Inc. is led by CEO Adrian H. Gottschalk, employs 112 people, headquartered in US, publicly traded since 2020.

Foghorn Therapeutics Inc. (FHTX) stock trades at $5.20 with a market capitalization of $305.31M. The stock is valued at a price-to-earnings (P/E) ratio of -4.15, price-to-book of -4.41, price-to-sales of 10.09. Over the past 52 weeks the stock has ranged between $3.27 and $6.95, and currently trades 25.2% below its 52-week high.

On profitability, Foghorn Therapeutics Inc. generates a return on equity (ROE) of 85.78% — well above the market average, a sign of a high-quality business, return on capital employed of -51.20%, an operating margin of -264.52%, a net profit margin of -266.88%.

Official website: foghorntx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides